OREANDA-NEWS. September 16, 2015. Celanese Corporation (NYSE: CE), a global technology and specialty materials company, will present its industry-leading innovation in pharmaceutical, controlled release ethylene vinyl acetate (EVA) copolymers at the Polymers in Medicine and Biology Conference, September 14-17 in Santa Rosa, Calif.

Celanese materials experts will discuss the challenges of developing and commercializing new innovations while trying to meet ever-changing regulatory requirements. And building upon clinically-approved materials technology, Celanese will discuss how it is helping to find middle ground and expand drug product technology.

“Our pharmaceutical EVA, VitalDose®, is a proven, controlled-release excipient that has been clinically approved in drug delivery systems for many years,” said Jose Reyes, strategic marketing manager. “New dosage forms, such as the foamed excipient, are changing the way new therapies and biologics could be delivered to the body and are offering new dimensions for immunogenic mitigation possibilities through the material’s customizable release profile capabilities.”

“Celanese collaborates with many early-stage investigators conducting the essential research into the improvement of human health using devices, drug products and systems that address chronic needs in metabolic disease, cancer, addiction, infection, women’s health, and combination therapies, among others,” said Don Loveday, strategic marketing manager.

Celanese presentation sessions:

  • Jose Reyes will present “Solving the Medical Polymers Paradox with Ethylene Vinyl Acetate Copolymers for Enabling Advanced Delivery of Proteins and Stem Cells” on Tuesday, September 15, 2015 at 9:00 a.m.
  • Don Loveday will lead the Entrepreneurship sessions on Wednesday, September 16, from 3:00 p.m. to 5:45 p.m., featuring presentations from ExThera, Google, Healionics, and Profusa, among others.

For more information about Celanese’s controlled release pharmaceutical EVA, VitalDose®, visit www.vitaldose.com.